Latest News & Updates from the HEALEY ALS Platform Trial
Jul 15, 2024 · The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in …
Sean M. Healey & AMG Center Announces Update in ALS Platform Trial …
BOSTON – The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital today announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating f …
Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS …
For updates on the trial, please join our HEALEY ALS Platform Trial webinars. The HEALEY ALS Platform Trial is a patient-centric clinical trial designed in collaboration with the Northeast ALS …
DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS
14 hours ago · Testing DNL343, fosigotifator in HEALEY trial. The main goal of all the arms is to evaluate a treatment’s ability to slow ALS progression and prolong survival, as assessed by …
Calico Provides Update on Fosigotifator in HEALEY ALS Platform Trial
4 days ago · The HEALEY ALS Platform Trial is a patient-centric clinical trial designed in collaboration with the Northeast ALS Consortium (NEALS) to accelerate the development of …
Fosigotifator Fails to Meet End Points in HEALEY-ALS Platform Trial
3 days ago · Topline data from regimen F of the HEALEY-ALS Platform trial revealed that fosigotifator (Calico Life Sciences), an investigational eIF2B activator, did not meet its primary …
HEALEY ALS trial to allow longer follow-up, blood cell collection
Dec 20, 2024 · The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a …
Patient enrollment complete in DNL343 arm of HEALEY ALS trial
May 14, 2024 · The HEALEY platform trial (NCT04297683), led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), in Boston, is the first study to ever …
Denali Therapeutics Announces Topline Results for Regimen G …
3 days ago · Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial Denali Therapeutics Inc. Mon, …
Denali Therapeutics announces HEALEY ALS trial regimen misses …
3 days ago · Denali Therapeutics announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of …
- Some results have been removed